No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
dactinomycin Sensitive: A1 - Approval
|
dactinomycin Sensitive: A1 - Approval
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
ifosfamide Sensitive: A1 - Approval
|
ifosfamide Sensitive: A1 - Approval
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
TI-CE Sensitive: A2 - Guideline
|
TI-CE Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
VC Sensitive: A2 - Guideline
|
VC Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
GemOx Sensitive: A2 - Guideline
|
GemOx Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
BEP Sensitive: A2 - Guideline
|
BEP Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
VIP Sensitive: A2 - Guideline
|
VIP Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
VAC Sensitive: A2 - Guideline
|
VAC Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
VeIP Sensitive: A2 - Guideline
|
VeIP Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
TIP Sensitive: A2 - Guideline
|
TIP Sensitive: A2 - Guideline
|
TMB-H
|
Germ Cell Tumors
|
TMB-H
|
Germ Cell Tumors
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
paclitaxel + ifosfamide Sensitive: A2 - Guideline
|
paclitaxel + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
paclitaxel + gemcitabine Sensitive: A2 - Guideline
|
paclitaxel + gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
etoposide IV Sensitive: A2 - Guideline
|
etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Germ Cell Tumors
|
No biomarker
|
Germ Cell Tumors
|
paclitaxel + gemcitabine + oxaliplatin Sensitive: A2 - Guideline
|
paclitaxel + gemcitabine + oxaliplatin Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Germ Cell Tumors
|
MSI-H/dMMR
|
Germ Cell Tumors
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Germ Cell Tumors
|
BRCA1 mutation
|
Germ Cell Tumors
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
XPA expression
|
Germ Cell Tumors
|
XPA expression
|
Germ Cell Tumors
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
MTOR mutation
|
Germ Cell Tumors
|
MTOR mutation
|
Germ Cell Tumors
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
KRAS amplification
|
Germ Cell Tumors
|
KRAS amplification
|
Germ Cell Tumors
|
MEK inhibitor Sensitive: C3 – Early Trials
|
MEK inhibitor Sensitive: C3 – Early Trials
|
Chr t(22)
|
Germ Cell Tumors
|
Chr t(22)
|
Germ Cell Tumors
|
cisplatin + ifosfamide + etoposide oral + mesna Sensitive: C4 – Case Studies
|
cisplatin + ifosfamide + etoposide oral + mesna Sensitive: C4 – Case Studies
|
EGFR L858R
|
Germ Cell Tumors
|
EGFR L858R
|
Germ Cell Tumors
|
icotinib Sensitive: C4 – Case Studies
|
icotinib Sensitive: C4 – Case Studies
|
BAX underexpression
|
Germ Cell Tumors
|
BAX underexpression
|
Germ Cell Tumors
|
cisplatin Resistant: C4 – Case Studies
|
cisplatin Resistant: C4 – Case Studies
|
TP53 mutation
|
Germ Cell Tumors
|
TP53 mutation
|
Germ Cell Tumors
|
cisplatin Resistant: C4 – Case Studies
|
cisplatin Resistant: C4 – Case Studies
|
EGFR L858R
|
Germ Cell Tumors
|
EGFR L858R
|
Germ Cell Tumors
|
icotinib Sensitive: C4 – Case Studies
|
icotinib Sensitive: C4 – Case Studies
|
MSH6 mutation
|
Germ Cell Tumors
|
MSH6 mutation
|
Germ Cell Tumors
|
camrelizumab Sensitive: C4 – Case Studies
|
camrelizumab Sensitive: C4 – Case Studies
|
BRCA2 mutation
|
Germ Cell Tumors
|
BRCA2 mutation
|
Germ Cell Tumors
|
camrelizumab Sensitive: C4 – Case Studies
|
camrelizumab Sensitive: C4 – Case Studies
|
PMS2 mutation
|
Germ Cell Tumors
|
PMS2 mutation
|
Germ Cell Tumors
|
camrelizumab Sensitive: C4 – Case Studies
|
camrelizumab Sensitive: C4 – Case Studies
|
PLAC8 overexpression
|
Germ Cell Tumors
|
PLAC8 overexpression
|
Germ Cell Tumors
|
etoposide oral Resistant: D – Preclinical
|
etoposide oral Resistant: D – Preclinical
|
BRCA1 expression
|
Germ Cell Tumors
|
BRCA1 expression
|
Germ Cell Tumors
|
olaparib Resistant: D – Preclinical
|
olaparib Resistant: D – Preclinical
|
RAD51C expression
|
Germ Cell Tumors
|
RAD51C expression
|
Germ Cell Tumors
|
olaparib Resistant: D – Preclinical
|
olaparib Resistant: D – Preclinical
|